• Markets
    • icon
  • Companies
RAD · ASX

Radiopharm Theranostics Limited (ASX:RAD)

AU$0.071

 0.0 (0.0%)
ASX:Live
05/12/2023 12:00:00 AM
Near Support Near 52 Week Low HALO Ords HALO Consensus Value GROWTH AUS +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RAD Overview

RAD Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About RAD

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053

Description

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

RAD Price Chart

Key Stats

Market Cap

AU$34.34M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.07 - 0.2

Trade Value (12mth)

AU$9,624.00

1 week

0%

1 month

-6.58%

YTD

-31.66%

1 year

-34.63%

All time high

0.451941

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

%

Operating Cashflow

-$23m

Free Cash Flow Return

-43.20%

ROIC

-64.50%

Interest Coverage

-429.70

Quick Ratio

1.20

Other Data

Shares on Issue (Fully Dilluted)

359m

HALO Sector

Healthcare

Next Company Report Date

26-Sep-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RAD Announcements

Latest Announcements

Date Announcements

31 October 23

Entitlement Offer to raise approximately $10 million

×

Entitlement Offer to raise approximately $10 million

31 October 23

Investor Presentation - Entitlement Offer

×

Investor Presentation - Entitlement Offer

31 October 23

Proposed issue of securities - RAD

×

Proposed issue of securities - RAD

31 October 23

Investor webinar

×

Investor webinar

31 October 23

Proposed issue of securities - RAD

×

Proposed issue of securities - RAD

31 October 23

Entitlement Offer cleansing notice under section 708AA

×

Entitlement Offer cleansing notice under section 708AA

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Change of Director's Interest Notice - RC

×

Change of Director's Interest Notice - RC

31 October 22

Change of Director's Interest Notice - PH

×

Change of Director's Interest Notice - PH

31 October 22

Change in substantial holding - PH

×

Change in substantial holding - PH

31 March 22

Change of Director's Interest Notice - HL

×

Change of Director's Interest Notice - HL

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 23

Appendix 4E and FY23 Financial Report

×

Appendix 4E and FY23 Financial Report

31 August 22

Appendix 4E and Preliminary Final Report

×

Appendix 4E and Preliminary Final Report

30 September 22

Annual Report to shareholders

×

Annual Report to shareholders

30 September 22

Corporate Governance Statement

×

Corporate Governance Statement

30 September 22

Appendix 4G

×

Appendix 4G

30 September 22

ESG Report

×

ESG Report

30 September 22

Corporate Governance Statement

×

Corporate Governance Statement

30 May 22

Notification regarding unquoted securities - RAD

×

Notification regarding unquoted securities - RAD

30 June 23

Notification regarding unquoted securities - RAD

×

Notification regarding unquoted securities - RAD

30 June 23

Notification of cessation of securities - RAD

×

Notification of cessation of securities - RAD

30 December 22

aVb6 Integrin (RAD301) IND approval for Phase 1 trial

×

aVb6 Integrin (RAD301) IND approval for Phase 1 trial

29 November 22

Change of Director's Interest Notice - PH

×

Change of Director's Interest Notice - PH

29 November 22

Change of Director's Interest Notice - RC

×

Change of Director's Interest Notice - RC

29 November 21

Investor Presentation

×

Investor Presentation

29 May 23

FDA Pre-IND meeting supports an IND application for RAD 101

×

FDA Pre-IND meeting supports an IND application for RAD 101

RAD Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.12 -0.11 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.12 -0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -5,957.9 7.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.05 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.04 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -9,552.5 -64.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A -25.9 -72.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock N/A 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock N/A 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock -0.00 0.24 0.12 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock -0.00 0.03 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 5,577.7 -251.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 262 264 324 Lock Lock Lock
Basic m Lock Lock Lock Lock 262 264 324 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 0 17 37 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A -0.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -1,027.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 1,128 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 0 -17 -37 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -3,395.3 -118.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -12,654.3 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 3 3 Lock Lock Lock
EBIT $m Lock Lock Lock Lock 0 -20 -40 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -4,010.4 -102.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -13,781.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock 0 -30 -40 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -6 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 0 -30 -35 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -6,169.7 -13.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -11,838.6 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 0 -10 -23 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 28 2 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -28 -2 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 65 9 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 0 -10 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -30,011.1 -134.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A -79.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 0 27 12 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 0 83 75 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 0 -27 -12 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 20 29 Lock Lock Lock
Equity $m Lock Lock Lock Lock 0 63 44 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 0 63 44 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 50,590.1 -29.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -1,451.0 -36.5 -46.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 389.1 -48.3 -78.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock N/A -63.4 -74.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock N/A -96.8 -64.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock N/A -31.5 -43.2 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A -1.8 -429.7 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -0.1 1.6 0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -25.6 -42.8 -26.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 0.2 3.5 1.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.2 3.5 1.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 81.0 99.0 71.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -20.8 -125.7 -175.4 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock N/A 0.0 0.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock N/A 0.0 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 1,011.3 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A -13,849.6 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A -54.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -1,451.0 -36.5 -46.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock -0.3 1.3 1.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 389.1 -48.3 -78.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock N/A 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock N/A -48.3 -78.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 2,824.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 2,824.3 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A 76.8 229.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock N/A -76.8 2,594.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAD Shortsell

Frequently Asked Questions

The current share price of Radiopharm Theranostics Limited (RAD:ASX) is AU$0.071.
The 52-week high share price for Radiopharm Theranostics Limited (RAD:ASX) is AU$0.20.
The 52-week low share price for Radiopharm Theranostics Limited (RAD:ASX)? is AU$0.07.
Radiopharm Theranostics Limited (RAD:ASX) does not pay a dividend.
Radiopharm Theranostics Limited (RAD:ASX) does not pay a dividend.
Radiopharm Theranostics Limited (RAD:ASX) has a franking level of 0%.
Radiopharm Theranostics Limited (RAD:ASX) is classified in the Healthcare.
The current P/E ratio for Radiopharm Theranostics Limited (RAD:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.